- Home
- ANVS vs AFMD Comparison
ANVS vs AFMD Comparison
Compare ANVS & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- AFMD
- Stock Information
- Founded
- ANVS 2008
- AFMD 2000
- Country
- ANVS United States
- AFMD Germany
- Employees
- ANVS N/A
- AFMD N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- AFMD Health Care
- Exchange
- ANVS Nasdaq
- AFMD Nasdaq
- Market Cap
- ANVS 110.4M
- AFMD 53.3M
- IPO Year
- ANVS 2020
- AFMD 2014
- Fundamental
- Price
- ANVS $9.57
- AFMD $3.36
- Analyst Decision
- ANVS Strong Buy
- AFMD Strong Buy
- Analyst Count
- ANVS 6
- AFMD 5
- Target Price
- ANVS $29.67
- AFMD $16.25
- AVG Volume (30 Days)
- ANVS 341.4K
- AFMD 80.0K
- Earning Date
- ANVS 11-06-2024
- AFMD 11-12-2024
- Dividend Yield
- ANVS N/A
- AFMD N/A
- EPS Growth
- ANVS N/A
- AFMD N/A
- EPS
- ANVS N/A
- AFMD N/A
- Revenue
- ANVS N/A
- AFMD $7,959,927.00
- Revenue This Year
- ANVS N/A
- AFMD N/A
- Revenue Next Year
- ANVS N/A
- AFMD $48.98
- P/E Ratio
- ANVS N/A
- AFMD N/A
- Revenue Growth
- ANVS N/A
- AFMD N/A
- 52 Week Low
- ANVS $4.53
- AFMD $2.92
- 52 Week High
- ANVS $22.49
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- AFMD 44.84
- Support Level
- ANVS $9.00
- AFMD $3.28
- Resistance Level
- ANVS $10.54
- AFMD $3.51
- Average True Range (ATR)
- ANVS 0.81
- AFMD 0.17
- MACD
- ANVS 0.12
- AFMD 0.04
- Stochastic Oscillator
- ANVS 74.57
- AFMD 55.79
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.